An In Vitro and In Silico Study of the Enhanced Antiproliferative and Pro-Oxidant Potential of <i>Olea europaea</i> L. cv. Arbosana Leaf Extract via Elastic Nanovesicles (Spanlastics)

• Main Authors: Taghreed S. Alnusaire (Author), Ahmed M. Sayed (Author), Abeer H. Elmaidomy (Author), Mohammad M. Al-Sanea (Author), Sarah Albogami (Author), Mha Albqmi (Author), Bassam F. Alowaiesh (Author), Ehab M. Mostafa (Author), Arafa Musa (Author), Khayrya A. Youssif (Author), Hesham Refaat (Author), Eman M. Othman (Author), Thomas Dandekar (Author), Eman Alaaeldin (Author), Mohammed M. Ghoneim (Author), Usama Ramadan Abdelmohsen (Author)
• Format: Book
• Published: MDPI AG, 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

The olive tree is a venerable Mediterranean plant and often used in traditional medicine. The main aim of the present study was to evaluate the effect of <i>Olea europaea</i> L. cv. Arbosana leaf extract (OLE) and its encapsulation within a spanlastic dosage form on the improvement of its pro-oxidant and antiproliferative activity against HepG-2, MCF-7, and Caco-2 human cancer cell lines. The LC-HRESIMS-assisted metabolomic profile of OLE putatively annotated 20 major metabolites and showed considerable in vitro antiproliferative activity against HepG-2, MCF-7, and Caco-2 cell lines with IC₅₀ values of 9.2 ± 0.8, 7.1 ± 0.9, and 6.5 ± 0.7 µg/mL, respectively. The encapsulation of OLE within a (spanlastic) nanocarrier system, using a spraying method and Span 40 and Tween 80 (4:1 molar ratio), was successfully carried out (size 41 ± 2.4 nm, zeta potential 13.6 ± 2.5, and EE 61.43 ± 2.03%). OLE showed enhanced thermal stability, and an improved in vitro antiproliferative effect against HepG-2, MCF-7, and Caco-2 (IC₅₀ 3.6 ± 0.2, 2.3 ± 0.1, and 1.8 ± 0.1 µg/mL, respectively) in comparison to the unprocessed extract. Both preparations were found to exhibit pro-oxidant potential inside the cancer cells, through the potential inhibitory activity of OLE against glutathione reductase and superoxide dismutase (IC₅₀ 1.18 ± 0.12 and 2.33 ± 0.19 µg/mL, respectively). These inhibitory activities were proposed via a comprehensive in silico study to be linked to the presence of certain compounds in OLE. Consequently, we assume that formulating such a herbal extract within a suitable nanocarrier would be a promising improvement of its therapeutic potential.

Item Description

10.3390/antiox10121860
2076-3921